DRugwatch BlogRSS 2.0

DRugwatch Blog > March 2012 > Payers Will Have the Final Say over PreP

Payers Will Have the Final Say over PreP

Contributors: LaTese Briggs, Ph.D. and Allison Thrower

In recent news on the HIV/AIDS front, the FDA is reviewing the possibility of marketing certain HIV drugs as a preventative measure for individuals who are healthy but at-risk for infection. However, research that was viewed optimistically over a year ago is coming under fire by the AIDS Healthcare Foundation (AHF) as the group petitioned against FDA approval due to questions of efficacy, high costs, side effects and patients’ lack of commitment to the regimen. Whether or not the petition sticks, the real-world, widespread use of this treatment ultimately comes down to the payers.

In reality, they won’t pay for it. Why would they pay for a preventative method that only reduces the risk of infection by 40-50% and can lead to other health problems? This is especially true considering there is a perfectly viable prevention method that works more than 90% of the time – condoms (the AHF’s preferred preventive measure).

In that sense, the AHF has a point to its accusations. The 40-50% risk reduction is highly contingent upon adherence, which is critical in the treatment of HIV. HIV-positive patients who do not adhere to antiretroviral (ARV) schedules are at high risk for the development of drug resistance, which is also sexually transmissible. Now if those who need ARVs to keep them alive have adherence problems, it’s unlikely to expect it from HIV-negative individuals whose lives aren’t dependent on taking these drugs, also known as Pre-exposure Prophylaxis (PreP). There is an accountability issue here. How do we enforce to people that, if they don’t take PreP as scheduled, they can both contract HIV and greatly increase the risk of becoming resistant to a number of key HIV drugs? As the question seems to have no workable answer, therapeutic options may be limited. Also, as aforementioned, certain resistance mutations can be sexually transmitted, which adds to the public health risk. Furthermore, administration of PreP will require consistent monitoring to A) make certain that patients are taking the drug to avoid the development of drug resistance and B) keep an eye on kidney toxicity associated with tenofovir (one of the nucleoside reverse-transcriptase inhibitors [NRTIs] in Truvada). Physicians are trying to eventually move away from using NRTIs because of the toxicity profiles associated with long-term exposure. So while treatments are very effective, the related safety risks add another plausible argument to oppose PreP from a patient, physician or payer perspective.

All in all, even if Truvada is approved, the payers will shut down any real commercial opportunities because they will refuse to cover it. There may be special exceptions, such as use in serodiscordant couples, but for the most part this will be something that people will likely have to pay for out of pocket.
Posted on: 3/14/2012 4:21:49 PM | with 0 comments


Tags: Allison Thrower, Infectious Disease, LaTese Briggs

Trackback URL: http://decisionresources.com/trackback/b1d1a54c-0fb2-4c6f-9b4d-9ced91465d59/Payers-Will-Have-the-Final-Say-over-PreP.aspx?culture=en-us

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Creating oral versions of injectable therapies for chronic diseases – a “win-win-win” concept
Post date:
3/6/2015 11:13:08 AM
Post Summary:

Stefanie MatlokContributor: Stefanie Hoffart
Therapeutic area: Cardiovascular and Metabolic Disorders

Novo Nordisk recently announced the first positive Phase 2 results for an oral GLP-1 analogue. Oral therapies are typically utilized in the early lines of therapy for type 2 diabetes, but as the disease progresses more aggressive treatment is required so patients can end up on multiple oral medications.


Post title:
Next Steps for Vorapaxar: EU PAD Label and Antidote Development?
Post date:
2/17/2015 10:49:37 AM
Post Summary:

Stefanie Matlok Graeme GreeneWriiten by: Stefanie Hoffart and Graeme Green

Topic: Cardiovascular

On January 19, 2015, the European Medicines Agency (EMA) approved the thrombin receptor antagonist vorapaxar (Merck’s Zontivity) for secondary prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI), co-administered with acetylsalicylic acid (ASA) and, if necessary, clopidogrel.


Post title:
Bococizumab: Late to Great? Dyslipidemia Déjà vu?
Post date:
2/12/2015 3:58:28 PM
Post Summary:
Tim BlackstockContributor: Tim Blackstock
Topics: Cardiovascular

The link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well established, as is, the evidence showing that agents that reduce LDL-C can prevent CV events.

Post title:
Sandoz’s Biosimilar Filgrastim Scores Positive Recommendation from FDA Advisory Committee
Post date:
1/22/2015 3:44:26 PM
Post Summary:
Contributors: Anees Malik and Hristina Ivanova

The unanimous recommendation by the Oncologic Drugs Advisory Committee (ODAC) for FDA approval of Sandoz’s biosimilar filgrastim (EP2006; Zarxio)–the first biosimilar filing to be accepted in the United States– moves the biosimilar product tantalizingly close to FDA approval. Oncology, Biosimilars, “Anees Malik”, “Hristina Ivanova”

Post title:
AstraZeneca’s Brilinta Meets Primary End Point in PEGASUS-TIM 54 Study
Post date:
1/15/2015 4:53:03 PM
Post Summary:
Conor WalshContributor: Conor Walsh

AstraZeneca yesterday (January 14, 2015) announced that the Phase III PEGASUS-TIMI 54 study—a large-scale outcomes trial involving over 21,000 post-myocardial infarction (MI) patients—successfully met its primary efficacy end point. The company also reported that preliminary analysis did not reveal any unexpected safety issues. This study represents the first of several large studies that are set to complete over the next two years seeking to expand Brilinta’s (ticagrelor) label and drive sales growth.

Decision Resources Group brands include: